DaVita HealthCare Partners Inc. 3rd Quarter 2015 Results

03 Nov, 2015, 16:03 ET from DaVita HealthCare Partners Inc.

DENVER, Nov. 3, 2015 /PRNewswire/ -- DaVita HealthCare Partners Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2015. Net income attributable to DaVita HealthCare Partners Inc. for the three months ended September 30, 2015 was $216 million, or $1.00 per share.

Adjusted net income attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2015 was $610 million, or $2.80 per share, excluding after-tax debt redemption charges, after-tax settlement charge related to the Vainer suit and a related tax adjustment. Net income attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2015 including these items was $276 million, or $1.27 per share.

Adjusted net income attributable to DaVita HealthCare Partners Inc. for the three months ended September 30, 2014 was $195 million, or $0.90 per share, excluding an after-tax loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations. Adjusted net income attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2014 was $584 million, or $2.69 per share, excluding after-tax debt redemption and refinancing charges, and an after-tax loss contingency accrual as discussed above. Net income attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2014 including these items was $184 million and $515 million, or $0.85 and $2.38 per share, respectively.

See schedules of reconciliations of non-GAAP measures.

Financial and operating highlights include:

  • Cash Flow:  For the rolling twelve months ended September 30, 2015, operating cash flow was $1.051 billion and free cash flow was $602 million. For the three and nine months ended September 30, 2015, operating cash flow was $679 million and $1.121 billion, respectively, and free cash flow was $557 million and $799 million, respectively. Operating cash flow and free cash flow for the nine months ended and rolling twelve months ended September 30, 2015 were negatively impacted by approximately $304 million of after-tax payments made during the second quarter of 2015 in connection with the settlement of the Vainer suit.  In addition, the rolling twelve months ended September 30, 2015 was negatively impacted by approximately $269 million of after-tax payments made in connection with the settlement of the 2010 and 2011 U.S. Attorney physician relationship investigations. Excluding these items, operating cash flow for the nine months ended and the rolling twelve months ended September 30, 2015 would have been $1.424 billion and $1.623 billion, respectively.
  • Operating Income and Adjusted Operating Income:  Operating income for the three months ended September 30, 2015 was $509 million. Adjusted operating income for the nine months ended September 30, 2015 was $1.421 billion, excluding a settlement charge of $495 million related to the Vainer suit. Operating income for the nine months ended September 30, 2015, including this item was $926 million.

For the quarter ended September 30, 2015, we recognized a net benefit of approximately $22 million in our HCP segment, related to the recognition of certain risk sharing settlements. In addition, we reserved $23 million for refunds of prior period reimbursements in our pharmacy business.

Adjusted operating income for the three and nine months ended September 30, 2014 was $455 million and $1.380 billion, respectively, excluding a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations. Operating income for the three and nine months ended September 30, 2014 including this item was $438 million and $1.363 billion, respectively.

  • Adjusted Diluted Net Income Per ShareAdjusted net income attributable to DaVita HealthCare Partners Inc. for the three months ended September 30, 2015, excluding the amortization of intangible assets associated with acquisitions, net of tax, was $241 million and adjusted diluted net income per share was $1.12.  Adjusted net income attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2015, as adjusted to exclude additional certain other non-GAAP measures was $687 million, and adjusted diluted net income per share was $3.16.

Adjusted net income attributable to DaVita HealthCare Partners Inc. for the three months ended September 30, 2014, as adjusted to further exclude certain items was $220 million, and adjusted diluted net income per share was $1.01.  Adjusted net income attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2014, as adjusted to exclude additional certain other non-GAAP measures was $659 million, and adjusted diluted net income per share was $3.04.

See schedules of reconciliations of non-GAAP measures.

  • Volume:  Total U.S. dialysis treatments for the third quarter of 2015 were 6,611,799, or 83,694 treatments per day, representing a per day increase of 4.2% over the third quarter of 2014. Non-acquired treatment growth and normalized non-acquired treatment growth in the third quarter of 2015 were 4.0% and 3.5%, respectively.

The number of member months for which HCP provided capitated care during the third quarter of 2015 specifically related to its legacy markets was approximately 2.4 million, which was flat compared to the third quarter of 2014, inclusive of growth contributed from acquisitions.  

  • Effective Tax Rate:  Our effective tax rate was 36.0% and 31.9% for the three and nine months ended September 30, 2015, respectively. This effective tax rate is impacted by the amount of third party owners' income attributable to non-tax paying entities. The effective tax rate attributable to DaVita HealthCare Partners Inc. was 40.5% and 39.9% for the three and nine months ended September 30, 2015, respectively. The adjusted effective tax rate attributable to DaVita HealthCare Partners Inc. excluding the Vainer suit settlement charge was 39.2% for the nine months ended September 30, 2015.

We currently expect our 2015 effective tax rate attributable to DaVita HealthCare Partners Inc. to be approximately 39.0% to 40.0%, excluding the Vainer suit settlement charge.

  • Center Activity:  As of September 30, 2015, we provided dialysis services to a total of approximately 187,000 patients at 2,329 outpatient dialysis centers, of which 2,225 centers are located in the United States and 104 centers are located in ten countries outside of the United States. During the third quarter of 2015, we acquired five dialysis centers, opened a total of 15 new dialysis centers, and closed five dialysis centers in the United States. We also acquired six, and opened two new dialysis centers outside of the United States.
  • Share Repurchases:  During the three months ended September 30, 2015, we repurchased a total of 4,555,868 shares of our common stock for $341 million, or an average price of $74.76 per share. During the nine months ended September 30, 2015, we repurchased 5,623,007 shares of our common stock for $425 million, or an average price of $75.53 per share. We also repurchased 2,200 shares of our common stock for $0.2 million, or an average price of $71.01 per share, of our common stock subsequent to September 30, 2015. As a result of these transactions we now have a total of approximately $659 million remaining under our current board authorization for share repurchases.

Outlook

  • We are updating our consolidated operating income for 2015 to now be in the range of $1.870 billion to $1.915 billion.

Our previous consolidated operating income guidance for 2015 was in the range of $1.825 billion to $1.925 billion.

  • We are also updating our operating income for Kidney Care for 2015 to now be in the range of $1.630 billion to $1.655 billion.

Our previous operating income guidance for Kidney Care for 2015 was in the range of $1.600 billion to $1.650 billion.

  • We are updating our operating income for HCP for 2015 to now be in the range of $240 million to $260 million.

Our previous operating income guidance for HCP for 2015 was in the range of $225 million to $275 million.

  • We are updating our consolidated operating cash flows for 2015 to now be in the range of $1.675 billion to $1.775 billion.

Our previous consolidated operating cash flow for 2015 was in the range of $1.600 billion to $1.750 billion.

The above projected ranges exclude the Vainer suit settlement charge and the corresponding settlement payments made in 2015.

These projections and the underlying assumptions involve significant risks and uncertainties, including those described below, and actual results may vary significantly from these current projections.

We will be holding a conference call to discuss our results for the third quarter ended September 30, 2015 on November 3, 2015 at 5:00 p.m. Eastern Time. To join the conference call, please dial (888) 282-0359 from the U.S. or (312) 470-7167 from outside the U.S. A replay of the conference call will be available on our website at investors.davitahealthcarepartners.com, for the following 30 days.

This release contains forward-looking statements within the meaning of the federal securities laws, including statements related to our guidance and expectations for our 2015 consolidated operating income, our 2015 Kidney Care operating income, HCP's 2015 operating income, our 2015 consolidated operating cash flows and our 2015 effective tax rate attributable to DaVita HealthCare Partners Inc. Factors that could impact future results include the uncertainties associated with the risk factors set forth in our SEC filings, including our annual report on Form 10-K for the year ended December 31, 2014, our subsequent quarterly and annual reports, and our current reports on Form 8-K. The forward-looking statements should be considered in light of these risks and uncertainties.

These risks and uncertainties include, but are not limited to, and are qualified in their entirety by reference to the full text of those risk factors in our SEC filings relating to:

  • the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates, and a reduction in the number of patients under such plans, which may result in the loss of revenues or patients,
  • a reduction in government payment rates under the Medicare End Stage Renal Disease program or other government-based programs,
  • the impact of the Center for Medicare and Medicaid Services (CMS) 2015 Medicare Advantage benchmark structure,
  • risks arising from potential federal and/or state legislation that could have an adverse effect on our operations and profitability,
  • changes in pharmaceutical or anemia management practice patterns, payment policies, or pharmaceutical pricing, 
  • legal compliance risks, including our continued compliance with complex government regulations and including compliance with the provisions of our current corporate integrity agreement and current or potential investigations by various government entities and related government or private-party proceedings, and restrictions on our business and operations required by our corporate integrity agreement and other settlement terms, and the financial impact thereof,
  • continued increased competition from large- and medium-sized dialysis providers that compete directly with us,
  • our ability to maintain contracts with physician medical directors, changing affiliation models for physicians, and the emergence of new models of care introduced by the government or private sector, that may erode our patient base and reimbursement rates, such as accountable care organizations, independent practice associations and integrated delivery systems, or to businesses outside of dialysis and HealthCare Partners' (HCP) business,
  • our ability to complete acquisitions, mergers or dispositions that we might be considering or announce, or to integrate and successfully operate any business we may acquire or have acquired, including HCP, or to expand our operations and services to markets outside the United States,
  • the variability of our cash flows,
  • the risk that we might invest material amounts of capital and incur significant costs in connection with the growth and development of our international operations, yet we might not be able to operate them profitably anytime soon, if at all,
  • risks arising from the use of accounting estimates, judgments and interpretations in our financial statements,
  • loss of key HCP employees, potential disruption from the HCP transaction making it more difficult to maintain business and operational relationships with customers, partners, associated physicians and physician groups, hospitals and others,
  • the risk that laws regulating the corporate practice of medicine could restrict the manner in which HCP conducts its business,
  • the risk that the cost of providing services under HCP's agreements may exceed our compensation,
  • the risk that reductions in reimbursement rates, including Medicare Advantage rates, and future regulations may negatively impact HCP's business, revenue and profitability,
  • the risk that HCP may not be able to successfully establish a presence in new geographic regions or successfully address competitive threats that could reduce its profitability,
  • the risk that a disruption in HCP's healthcare provider networks could have an adverse effect on HCP's business operations and profitability,
  • the risk that reductions in the quality ratings of health maintenance organization plan customers of HCP could have an adverse effect on HCP's business, or
  • the risk that health plans that acquire health maintenance organizations may not be willing to contract with HCP or may be willing to contract only on less favorable terms.

We base our forward-looking statements on information currently available to us at the time of this release, and except as required by law we undertake no obligation to update or revise any forward-looking statements, whether as a result of changes in underlying factors, new information, future events or otherwise.

This release contains non-GAAP financial measures. For reconciliations of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see the attached reconciliation schedules. For the reasons stated in the reconciliation schedules, we believe our presentation of non-GAAP financial measures provides useful supplemental information for investors.

DAVITA HEALTHCARE PARTNERS INC. CONSOLIDATED STATEMENTS OF INCOME (unaudited) (dollars in thousands, except per share data)

Three months ended September 30,  

Nine months ended September 30,  

2015

2014

2015

2014

Patient service revenues...............................................................................................................................................................................................

$     2,414,034

$2,242,533

$ 7,049,428

$     6,543,880

Less: Provision for uncollectible accounts................................................................................................................................................................

(109,452 )

(98,971 )

(314,581 )

(270,220 )

Net patient service revenues.............................................................................................................................................................................

2,304,582

2,143,562

6,734,847

6,273,660

Capitated revenues........................................................................................................................................................................................................

926,847

848,546

2,643,552

2,435,480

Other revenues...............................................................................................................................................................................................................

294,236

259,716

869,849

757,949

Total net revenues...............................................................................................................................................................................................

3,525,665

3,251,824

10,248,248

9,467,089

Operating expenses and charges:

Patient care costs and other costs....................................................................................................................................................................

2,501,015

2,326,534

7,309,703

6,752,844

General and administrative.................................................................................................................................................................................

353,492

322,822

1,047,318

905,519

Depreciation and amortization...........................................................................................................................................................................

162,062

149,196

474,694

437,682

Provision for uncollectible accounts................................................................................................................................................................

2,511

3,961

6,497

9,680

Equity investment income..................................................................................................................................................................................

(2,783 )

(5,225 )

(10,724 )

(18,692 )

Loss contingency accrual and settlement charge..........................................................................................................................................

17,000

495,000

17,000

Total operating expenses and charges..................................................................................................................................................

3,016,297

2,814,288

9,322,488

8,104,033

Operating income...........................................................................................................................................................................................................

509,368

437,536

925,760

1,363,056

Debt expense...................................................................................................................................................................................................................

(103,481 )

(99,878 )

(305,121 )

(312,345 )

Debt redemption and refinancing charges.................................................................................................................................................................

(48,072 )

(97,548 )

Other income (loss), net................................................................................................................................................................................................

2,484

(1,246 )

4,262

2,145

Income before income taxes..........................................................................................................................................................................................

408,371

336,412

576,829

955,308

Income tax expense........................................................................................................................................................................................................

147,064

116,628

183,893

342,366

Net income.......................................................................................................................................................................................................................

261,307

219,784

392,936

612,942

Less: Net income attributable to noncontrolling interests............................................................................................................................

(45,435 )

(35,662 )

(117,204 )

(97,848 )

Net income attributable to DaVita HealthCare Partners Inc.....................................................................................................................................

$        215,872

$    184,122

$     275,732

$        515,094

Earnings per share:

Basic net income per share attributable to DaVita HealthCare Partners Inc...............................................................................................

$              1.02

$          0.87

$           1.30

$              2.43

Diluted net income per share attributable to DaVita HealthCare Partners Inc...........................................................................................

$              1.00

$          0.85

$           1.27

$              2.38

Weighted average shares for earnings per share:

Basic......................................................................................................................................................................................................................

212,374,897

212,617,238

212,914,126

212,086,735

Diluted...................................................................................................................................................................................................................

216,691,461

217,236,493

217,421,213

216,695,033

DAVITA HEALTHCARE PARTNERS INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (dollars in thousands)

Three months ended

September 30,

Nine months ended

September 30,

2015

2014

2015

2014

Net income......................................................................................................................................................................

$    261,307

$    219,784

$    392,936

$   612,942

Other comprehensive (loss) income, net of tax:

Unrealized losses on interest rate swap and cap agreements:

Unrealized (losses) gains on interest rate swap and cap agreements.............................................................

(1,851)

537

(10,064)

(7,177)

Reclassifications of net swap and cap agreements realized losses into net income.......................................

771

1,403

2,372

9,759

Unrealized (losses) gains on investments:

Unrealized (losses) gains on investments.........................................................................................................

(1,651)

(392)

(1,368)

517

Reclassification of net investment realized gains into net income.....................................................................

(203)

(376)

(207)

Foreign currency translation adjustments.....................................................................................................................

(7,023)

(13,838)

(19,883)

(11,871)

Other comprehensive loss..................................................................................................................................

(9,957)

(12,290)

(29,319)

(8,979)

Total comprehensive income..........................................................................................................................................

251,350

207,494

363,617

603,963

Less: Comprehensive income attributable to noncontrolling interests...............................................................

(45,435)

(35,662)

(117,204 )

(97,848 )

Comprehensive income attributable to DaVita HealthCare Partners Inc........................................................................

$    205,915

$   171,832

$    246,413

$ 506,115

DAVITA HEALTHCARE PARTNERS INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (dollars in thousands)  

Nine months ended September 30,

2015

2014

Cash flows from operating activities:

Net income.......................................................................................................................................................

$           392,936

$           612,942

Adjustments to reconcile net income to cash provided by operating activities:

Settlement charge and loss contingency accrual...............................................................................

495,000

17,000

Settlement payments............................................................................................................................

(493,775 )

Depreciation and amortization..............................................................................................................

474,694

437,335

Debt redemption and refinancing charges...........................................................................................

48,072

97,548

Stock-based compensation expense...................................................................................................

42,794

44,323

Tax benefits from stock award exercises...........................................................................................

31,069

45,527

Excess tax benefits from stock award exercises...............................................................................

(19,555 )

(32,665 )

Deferred income taxes..........................................................................................................................

(1,994 )

(2,167 )

Equity investment income, net...............................................................................................................

10,563

6,007

Other non-cash charges and loss on disposal of assets....................................................................

26,583

30,604

Changes in operating assets and liabilities, other than from acquisitions and divestitures:

Accounts receivable............................................................................................................................

(178,148 )

16,610

Inventories............................................................................................................................................

(35,856 )

(25,198 )

Other receivables and other current assets......................................................................................

54,924

7,563

Other long-term assets........................................................................................................................

1,940

2,622

Accounts payable................................................................................................................................

11,473

2,332

Accrued compensation and benefits.................................................................................................

123,081

147,570

Other current liabilities........................................................................................................................

96,671

72,932

Income taxes........................................................................................................................................

35,282

72,283

Other long-term liabilities.....................................................................................................................

4,773

(23,770 )

Net cash provided by operating activities................................................................................

1,120,527

1,529,398

Cash flows from investing activities:

Additions of property and equipment...................................................................................................

(462,213 )

(443,507 )

Acquisitions..........................................................................................................................................

(90,709 )

(218,117 )

Proceeds from asset and business sales...........................................................................................

6,865

3,620

Purchase of investments available for sale........................................................................................

(6,667 )

(7,138 )

Purchase of investments held-to-maturity..........................................................................................

(1,555,604 )

(163,046 )

Proceeds from sale of investments available for sale........................................................................

1,961

1,321

Proceeds from investments held-to-maturity.......................................................................................

969,549

27,781

Purchase of intangible assets...............................................................................................................

(50 )

Purchase of equity investments.........................................................................................................

(13,623 )

(32,483 )

Distributions received on equity investments.....................................................................................

57

434

Net cash used in investing activities......................................................................................

(1,150,384 )

(831,185 )

Cash flows from financing activities:

Borrowings............................................................................................................................................

41,371,392

46,619,292

Payments on long-term debt and other financing costs................................................................

(40,732,075 )

(46,587,984 )

Deferred financing costs and debt redemption and refinancing costs........................................

(59,354 )

(122,154 )

Purchase of treasury stock.................................................................................................................

(384,110 )

Distributions to noncontrolling interests.........................................................................................

(125,938 )

(105,143 )

Stock award exercises and other share issuances, net...................................................................

19,802

14,524

Excess tax benefits from stock award exercises...............................................................................

19,555

32,665

Contributions from noncontrolling interests...................................................................................

28,212

38,083

Proceeds from sales of additional noncontrolling interests..........................................................

3,777

Purchase of noncontrolling interests................................................................................................

(23,605 )

(12,069 )

Net cash provided by (used in)financing activities.............................................................

113,879

(119,009 )

Effect of exchange rate changes on cash and cash equivalents.............................................................

(1,844 )

1,582

Net increase in cash and cash equivalents.................................................................................................

82,178

580,786

Cash and cash equivalents at beginning of the year................................................................................

965,241

946,249

Cash and cash equivalents at end of the period........................................................................................

$        1,047,419

$        1,527,035

DAVITA HEALTHCARE PARTNERS INC. CONSOLIDATED BALANCE SHEETS (unaudited) (dollars in thousands, except per share data)

September 30,

2015

December 31, 2014 

ASSETS

Cash and cash equivalents.................................................................................................................................

$         1,047,419

$        965,241

Short-term investments.......................................................................................................................................

922,848

337,399

Accounts receivable, less allowance of $261,850 and $242,674....................................................................

1,699,892

1,525,849

Inventories............................................................................................................................................................

173,050

136,085

Other receivables..................................................................................................................................................

416,932

400,916

Other current assets.............................................................................................................................................

175,715

186,842

Income tax receivable...........................................................................................................................................

48,963

83,839

Deferred income taxes..........................................................................................................................................

253,067

240,626

Total current assets...................................................................................................................................

4,737,886

3,876,797

Property and equipment, net of accumulated depreciation of $2,305,141 and $2,029,506.........................

2,621,918

2,469,099

Intangibles, net of accumulated amortization of $751,806 and $621,891......................................................

1,826,782

1,949,498

Equity investments..............................................................................................................................................

67,883

65,637

Long-term investments........................................................................................................................................

90,393

89,389

Other long-term assets........................................................................................................................................

62,387

77,000

Goodwill.................................................................................................................................................................

9,487,579

9,415,295

$       18,894,828

$   17,942,715

LIABILITIES AND EQUITY

Accounts payable................................................................................................................................................

$            487,945

$        445,453

Other liabilities......................................................................................................................................................

632,331

510,223

Accrued compensation and benefits................................................................................................................

835,518

698,475

Medical payables.................................................................................................................................................

340,143

314,347

Current portion of long-term debt......................................................................................................................

114,617

120,154

Total current liabilities..............................................................................................................................

2,410,554

2,088,652

Long-term debt.....................................................................................................................................................

9,082,096

8,383,280

Other long-term liabilities....................................................................................................................................

406,035

389,806

Deferred income taxes..........................................................................................................................................

906,807

890,701

Total liabilities............................................................................................................................................

12,805,492

11,752,439

Commitments and contingencies:

Noncontrolling interests subject to put provisions.............................................................................

897,139

829,965

Equity:

Preferred stock ($0.001 par value, 5,000,000 shares authorized; none issued).................................

Common stock ($0.001 par value, 450,000,000 shares authorized; 216,632,600 and 215,640,968 shares issued and 211,009,593 and 215,640,968 shares outstanding, respectively)...................

217

216

Additional paid-in capital.........................................................................................................................

1,106,342

1,108,211

Retained earnings......................................................................................................................................

4,362,835

4,087,103

Treasury stock (5,623,007 shares)...........................................................................................................

(424,705)

Accumulated other comprehensive loss................................................................................................

(54,336)

(25,017)

Total DaVita HealthCare Partners Inc. shareholders' equity...................................................

4,990,353

5,170,513

Noncontrolling interests not subject to put provisions......................................................................

201,844

189,798

Total equity................................................................................................................................................

5,192,197

5,360,311

$       18,894,828

$   17,942,715

DAVITA HEALTHCARE PARTNERS INC. SUPPLEMENTAL FINANCIAL DATA (unaudited) (dollars in millions, except for per share and per treatment data)

Three months ended

Nine months ended September 30, 2015

September 30,

2015

June 30,

2015

September 30,

2014

1. Consolidated Financial Results:

Consolidated net revenues.................................................................................................................................

$      3,526

$ 3,435

$      3,252

$    10,248

Operating income...............................................................................................................................................

$         509

$    481

$         438

$         926

Adjusted operating income excluding certain items (1).......................................................................................

$         509

$    481

$         455

$      1,421

Operating income margin....................................................................................................................................

14.4%

14.0%

13.5%

9.0%

Adjusted operating income margin excluding certain items (1)...........................................................................

14.4%

14.0%

14.0%

13.9%

Net income attributable to DaVita HealthCare Partners Inc.................................................................................

$         216

$    170

$         184

$         276

Adjusted net income attributable to DaVita HealthCare Partners Inc. excluding certain items (1)......................

$         216

$     207

$         195

$         610

Diluted net income per share attributable to DaVita HealthCare Partners Inc.....................................................

$        1.00

$    0.78

$        0.85

$        1.27

Adjusted diluted net income per share attributable to DaVita HealthCare Partners Inc. excluding certain items (1)...............................................................................................................................................................

$        1.00

$    0.95

$        0.90

$        2.80

2. Consolidated Business Metrics:

Expenses

General and administrative expenses as a percent of consolidated net revenues(2) ...............................

10.0%

10.2%

9.9%

10.2%

Consolidated effective tax rate ..................................

36.0%

37.1%

34.7%

31.9%

Consolidated effective tax rate attributable to DaVita HealthCare Partners Inc.(1) .....................................

40.5%

41.8%

38.7%

39.9%

Adjusted consolidated effective tax rate attributable to DaVita HealthCare Partners Inc.(1).......................

40.5%

39.2%

38.7%

39.2%

3. Summary of Division Financial Results:

Net revenues

Kidney Care:

Net dialysis and related lab services revenues.......................................................................................

$       2,201

$  2,154

$      2,076

$      6,426

Net ancillary services and strategic initiatives revenues, including international dialysis operations.................................................................................................................................................

345

334

300

984

Elimination of intersegment revenues.......................................................................................................

(21)

(19)

(16)

(57)

Total Kidney Care net revenues......................................................................................................

2,525

2,469

2,360

7,353

Net HCP revenues........................................................................................................................................

1,001

966

892

2,895

Total net consolidated revenues.....................................................................................................

$       3,526

$   3,435

$      3,252

$    10,248

Operating income

Kidney Care:

Dialysis and related lab services operating income

$          462

$      438

$         400

$         795

Other – Ancillary services and strategic initiatives, including international dialysis operations operating loss...........................................................................................................................................

(30)

(26)

(6)

(70)

Corporate support and related long-term incentive compensation...........................................................

(6)

(3)

(3)

(14)

Total Kidney Care operating income................................................................................................

426

409

391

711

HCP operating income..................................................................................................................................

83

72

47

215

Total consolidated operating income...............................................................................................

$         509

$      481

$         438

$         926

DAVITA HEALTHCARE PARTNERS INC. SUPPLEMENTAL FINANCIAL DATA—continued (unaudited) (dollars in millions, except for per share and per treatment data)

Three months ended

Nine months ended September 30, 2015

September 30, 2015

June 30,

 2015

September 30, 2014

4. Summary of Reportable Segment Financial Results:

Dialysis and Related Lab Services

Revenue:

Patient services revenues.............................................................................................

$    2,301

$  2,252

$      2,165

$      6,718

Provision for uncollectible accounts...........................................................................

(103)

(101)

(92)

(302)

Net patient service operating revenues..............................................................

2,198

2,151

2,073

6,416

Other revenues...............................................................................................................

3

3

3

10

Total net operating revenues...............................................................................

$       2,201

$      2,154

$      2,076

$      6,426

Operating expenses:

Patient care costs...........................................................................................................

$      1,461

$  1,436

$      1,390

$      4,294

General and administrative............................................................................................

170

174

170

528

Depreciation and amortization......................................................................................

112

110

102

326

Equity investment income.............................................................................................

(4)

(4)

(3)

(12)

Loss contingency accrual and settlement charge.....................................................

17

495

Total operating expenses......................................................................................

1,739

1,716

1,676

5,631

Segment operating income............................................................................................

$          462

$         438

$         400

$          795

HCP

Revenue:

HCP capitated revenues................................................................................................

$          907

$         848

$         828

$       2,588

Patient services revenues.............................................................................................

84

86

56

252

Provision for uncollectible accounts...........................................................................

(5)

(4)

(6)

(11)

Net patient service operating revenues..............................................................

79

82

50

241

Other revenues...............................................................................................................

15

36

14

66

Total net operating revenues...............................................................................

$       1,001

$         966

$         892

$       2,895

Operating expenses:

Patient care costs...........................................................................................................

$         768

$      750

$         719

$       2,250

General and administrative............................................................................................

106

102

86

300

Depreciation and amortization......................................................................................

43

43

42

130

Equity investment loss (income)..................................................................................

1

(1)

(2)

Total operating expenses......................................................................................

918

894

845

2,680

Segment operating income............................................................................................

$           83

$          72

$           47

$          215

5. Dialysis and Related Lab Services Business Metrics:

Volume

Treatments..........................................................................................................................

6,611,799

6,463,058

6,343,706

19,337,492

Number of treatment days................................................................................................ ........................................................................................................................................

79.0

78.0

79.0

233.6

Treatments per day............................................................................................................

83,694

82,860

80,300

82,780

Per day year over year increase.......................................................................................

4.2%

4.3%

5.1%

4.3%

Non-acquired growth year over year..............................................................................

4.0%

3.7%

4.4%

3.8%

Normalized non-acquired growth year over year..........................................................

3.5%

3.7%

4.9%

3.9%

Operating revenues before provision for uncollectible accounts

Dialysis and related lab services revenue per treatment.............................................

$    348.01

$    348.32

$    341.22

$    347.43

Per treatment (decrease) increase from previous quarter............................................

(0.1%)

0.7%

0.4%

Per treatment increase from previous year.....................................................................

2.0%

2.5%

0.4%

2.0%

Percent of net consolidated revenues............................................................................

62.9%

62.3%

63.5%

62.6%

DAVITA HEALTHCARE PARTNERS INC. SUPPLEMENTAL FINANCIAL DATA—continued (unaudited) (dollars in millions, except for per share and per treatment data)

Three months ended

Nine months ended September 30, 2015

September 30,

2015

June 30,

2015

September 30,

2014

5. Dialysis and Related Lab Services Business Metrics: (continued)

Expenses

Patient care costs

Percent of total segment operating revenues............................................................

66.4%

66.7%

66.9%

66.8%

Per treatment...................................................................................................................

$    220.92

$   222.17

$    219.07

$    222.01

Per treatment decrease from previous quarter...........................................................

(0.6%)

(0.4%)

0.4%

Per treatment increase from previous year.................................................................

0.8%

1.4%

0.9%

1.0%

General and administrative expenses

Percent of total segment operating revenues............................................................

7.7%

8.1%

8.2%

8.2%

Per treatment...................................................................................................................

$      25.78

$     26.99

$      26.86

$      27.31

Per treatment (decrease) increase from previous quarter.........................................

(4.5%)

(7.7%)

1.5%

Per treatment (decrease) increase from previous year..............................................

(4.0%)

2.0%

(11.3%)

3.3%

Accounts receivable

Net receivables...............................................................................................................

$      1,243

$     1,227

$      1,117

DSO..................................................................................................................................

51

53

50

Provision for uncollectible accounts as a percentage of revenues........................

4.5%

4.5%

4.25%

4.5%

6. HCP Business Metrics:

Capitated membership

Total.....................................................................................................................................

808,300

826,500

828,300

Member months.................................................................................................................

2,445,300

2,472,400

2,481,100

7,400,100

Capitated revenues by sources

Commercial revenues........................................................................................................

$         181

$        177

$          188

$          543

Senior revenues.................................................................................................................

641

623

605

1,866

Medicaid revenues............................................................................................................

85

48

35

179

Total capitated revenues...........................................................................................

$         907

$        848

$          828

$       2,588

Other

Total care dollars under management(1).........................................................................

$      1,260

$     1,245

$       1,148

$       3,738

Ratio of operating income to total care dollars under management(1).......................

6.6%

5.8%

4.0%

5.8%

Full time clinicians.............................................................................................................

1,311

1,272

1,153

IPA primary care physicians............................................................................................

2,935

3,018

3,313

7. Cash Flow:

Operating cash flow..........................................................................................................

$      679.0

$       31.4

$       847.9

$    1,120.5

Operating cash flow, last twelve months.......................................................................

$   1,050.5

$  1,219.4

$    1,883.6

Free cash flow(1)................................................................................................................

$      556.6

$     (76.9)

$       740.3

$       799.3

Free cash flow, last twelve months(1)..............................................................................

$      602.3

$     786.0

$    1,447.3

Capital expenditures:

Routine maintenance/IT/other..................................................................................

$        75.5

$       70.8

$         68.3

$       195.3

Development and relocations...................................................................................

$        95.8

$       98.7

$         96.6

$       266.9

Acquisition expenditures...........................................................................................

$        45.7

$         4.4

$       119.7

$         90.7

DAVITA HEALTHCARE PARTNERS INC. SUPPLEMENTAL FINANCIAL DATA—continued (unaudited) (dollars in millions, except for per share and per treatment data)

Three months ended

September 30,

2015

June 30,

2015

September 30,

2014

8. Debt and Capital Structure:

Total debt(3)..........................................................................................

$      9,211

$  9,225

$      8,519

Net debt, net of cash and cash equivalents(3).....................................

$      8,164

$  8,291

$      6,992

Leverage ratio (see calculation on page 14).......................................

2.93x

     3.03x

     2.79x

Overall weighted average effective interest rate during the quarter..................................................................................................

4.40%

4.42%

4.52%

Overall weighted average effective interest rate at end of the quarter..................................................................................................

4.40%

4.38%

4.46%

Weighted average effective interest rate on the Senior Secured Credit Facilities at end of the quarter...................................................

3.50%

3.44%

3.43%

Fixed and economically fixed interest rates as a percentage of our total debt..............................................................................................

      61%(4)

     61%(4)

57%

Fixed and economically fixed interest rates, including our interest rate cap agreements, as a percentage of our total debt....................

      90%(4)

     90%(4)

90%

9. Clinical: (quarterly averages)

Dialysis adequacy -% of patients with Kt/V > 1.2 at the end of the quarter..................................................................................................

97%

98%

98%

Dialysis patients with arteriovenous fistulas placed............................

73%

73%

73%

 

_________________

 

(1)     These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, and for a definition of adjusted amounts, see attached reconciliation schedules.

 

(2)     Consolidated percentages of revenues are comprised of the dialysis and related lab services business, HCP's business and other ancillary services and strategic initiatives. General and administrative expenses includes certain corporate support and related long-term incentive compensation.

 

(3)     The reported balance sheet amounts at September 30, 2015, June 30, 2015 and September 30, 2014, excludes $14.3 million, $14.9 million and $16.9 million, respectively, of a debt discount associated with our Term Loan B.

 

(4)     The Term Loan B is subject to a LIBOR floor of 0.75%. Because actual LIBOR, for all periods presented above, was lower than this embedded LIBOR floor, the interest rate on the Term Loan B is set at its respective floor. At such time as the actual LIBOR-based variable component of our interest rate exceeds 0.75% on the Term Loan B, we will then be subject to LIBOR-based interest rate volatility on the LIBOR variable component of our interest rate on all of the Term Loan B. However, we are limited to a maximum rate of 2.50% on $2.75 billion of outstanding principal debt on the Term Loan B as a result of interest rate cap agreements. The remaining $721 million outstanding principal balance of the Term Loan B is subject to LIBOR-based interest rate volatility above a floor of 0.75%.

DAVITA HEALTHCARE PARTNERS INC. SUPPLEMENTAL FINANCIAL DATA—continued (unaudited) (dollars in thousands)

Note 1: Calculation of the Leverage Ratio

Under the Senior Secured Credit Facilities (Credit Agreement), the leverage ratio is defined as all funded debt plus the face amount of all letters of credit issued, minus cash and cash equivalents, including short-term investments, divided by "Consolidated EBITDA". The leverage ratio determines the interest rate margin payable by the Company for its Term Loan A and revolving line of credit under the Credit Agreement by establishing the margin over the base interest rate (LIBOR) that is applicable. The following leverage ratio was calculated using "Consolidated EBITDA" as defined in the Credit Agreement. The calculation below is based on the last twelve months of "Consolidated EBITDA", pro forma for routine acquisitions that occurred during the period. The Company's management believes the presentation of "Consolidated EBITDA" is useful to investors to enhance their understanding of the Company's leverage ratio under its Credit Agreement.

Rolling twelve months ended

September 30, 2015

Net income attributable to DaVita HealthCare Partners Inc................................................................

$          483,752

Income taxes...............................................................................................................................................

287,870

Interest expense.........................................................................................................................................

379,502

Depreciation and amortization.................................................................................................................

627,947

Settlement charge......................................................................................................................................

495,000

Noncontrolling interests and equity investment income, net.............................................................

176,945

Stock-settled stock-based compensation..............................................................................................

55,443

Debt redemption charges.........................................................................................................................

48,072

Other ...........................................................................................................................................................

(22,888)

"Consolidated EBITDA"..................................................................................................................

$        2,531,643

September 30, 2015

Total debt, excluding debt discount of $14.3 million............................................................................

$         9,210,995

Letters of credit issued.............................................................................................................................

96,274

9,307,269

Less: Cash and cash equivalents including short-term investments (excluding HCP's physician owned entities cash)..........................................................................................................

(1,886,291)

Consolidated net debt...............................................................................................................................

$         7,420,978

Last twelve months "Consolidated EBITDA"......................................................................................

$         2,531,643

Leverage ratio.............................................................................................................................................

                   2.93x

In accordance with the Credit Agreement, the Company's leverage ratio cannot exceed 5.00 to 1.00 as of September 30, 2015. At that date the Company's leverage ratio did not exceed 5.00 to 1.00.

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands except for per share data)

1.   Adjusted net income and diluted net income per share attributable to DaVita HealthCare Partners Inc. excluding debt redemption and refinancing charges, a loss contingency accrual and a settlement charge, net of related tax, and tax adjustment related to the settlement of the Vainer suit.

We believe that adjusted net income attributable to DaVita HealthCare Partners Inc. excluding debt redemption and refinancing charges, a loss contingency accrual and settlement charge, net of related tax, and a tax adjustment related to the settlement of the Vainer suit, enhances a user's understanding of our normal net income attributable to DaVita HealthCare Partners Inc. and adjusted diluted net income per share attributable to DaVita HealthCare Partners Inc. for these periods by providing a measure that is meaningful because it excludes unusual amounts related to the debt redemption charges that resulted from the redemption of the $775 million 6 ⅝% Senior Notes due 2020, debt refinancing charges that resulted from the refinancing of our Secured Credit Facilities, the redemption of the $775 million 6 ⅜% Senior Notes due 2018, as well as the termination of certain interest rate swap agreements, and a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations, as well as a settlement charge, net of related tax, and tax adjustment related to the settlement of the Vainer suit, and accordingly, is comparable to prior periods and indicative of normal net income attributable to DaVita HealthCare Partners Inc. and diluted net income per share attributable to DaVita HealthCare Partners Inc. These measures are not measures of financial performance under United States generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income attributable to DaVita HealthCare Partners Inc. and diluted net income per share attributable to DaVita HealthCare Partners Inc.

Adjusted net income attributable to DaVita HealthCare Partners Inc. excluding debt redemption and refinancing charges, a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations, and a settlement charge, net of related tax, and tax adjustment related to the settlement of the Vainer suit:

Three months ended

Nine months ended

September 30,

2015

June 30,

2015

September 30,

2014

September 30,

2015

September 30,

2014

Net income attributable to DaVita HealthCare Partners Inc. ...............................................................................

$ 215,872

$170,477

$  184,122

$    275,732

$    515,094

Add:

Debt redemption and refinancing charges..........................

48,072

48,072

97,548

Loss contingency accrual..................................................

17,000

17,000

Settlement charge...............................................................

495,000

Tax adjustment related to the settlement of the Vainer suit......................................................................................

7,501

7,501

Less:  Related income tax...........................................................

(18,892)

(6,588)

(216,639)

(46,095)

$    215,872

$ 207,158

$  194,534

$    609,666

$    583,547

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands except for per share data)

Adjusted diluted net income per share attributable to DaVita HealthCare Partners Inc. excluding debt redemption and refinancing charges, a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations, and a settlement charge and tax adjustment related to the settlement of the Vainer suit:

Three months ended

Nine months ended

September 30,

2015

June 30,

2015

September 30,

2014

September 30,

2015

September 30,

2014

Diluted net income per share attributable to DaVita HealthCare Partners Inc...........................................................

$       1.00

$      0.78

$       0.85

$       1.27

$       2.38

Add:

Debt redemption and refinancing charges........................

0.13

0.13

0.26

Loss contingency accrual.................................................

0.05

0.05

Settlement charge..............................................................

1.36

Tax adjustment related to the settlement of the Vainer suit.........................................................................

0.04

0.04

$        1.00

$      0.95

$       0.90

$       2.80

$       2.69

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES – (continued) (unaudited) (dollars in thousands except for per share data)

In addition, we have excluded amortization of intangible assets associated with acquisitions from our adjusted net income attributable to DaVita HealthCare Partners Inc. and from our adjusted diluted net income per share attributable to DaVita HealthCare Partners Inc. as we believe this presentation enhances a user's understanding of our operating results for these periods by providing a different reflection of the Company's operating performance since it excludes the amortization of intangible assets that relate to the fair value measurement of acquired intangible assets associated with our acquisitions to fair value, and accordingly is indicative of consistent net income excluding amortization of acquired intangibles, attributable to DaVita HealthCare Partners Inc. and diluted net income per share attributable to DaVita HealthCare Partners Inc. These measures are not measures of financial performance under GAAP and should not be considered as an alternative to net income attributable to DaVita HealthCare Partners Inc. and diluted net income per share attributable to DaVita HealthCare Partners Inc.

Adjusted net income and adjusted diluted net income per share attributable to DaVita HealthCare Partners Inc., further adjusted to exclude the amortization of intangible assets associated with acquisitions:

Three months ended

Nine months ended

September 30,

2015

June 30,

2015

September 30,

2014

September 30,

2015

September 30,

2014

Adjusted net income attributable to DaVita HealthCare Partners Inc. .......................................................................

$  215,872

$207,158

$  194,534

$  609,666

$  583,547

Add:

Amortization of intangible assets associated with acquisitions for the dialysis and ancillary operations.....................................................................

6,285

6,384

6,673

19,193

20,253

Amortization of intangible assets associated with acquisitions for the HCP operations.............................

35,911

35,838

35,276

107,627

105,426

Less: Related income tax....................................................

(17,089)

(16,593)

(16,256)

(49,583)

(50,166)

$  240,979

$232,787

$  220,227

$  686,903

$  659,060

Adjusted diluted net income per share attributable to DaVita HealthCare Partners Inc.......................................

$        1.00

$     0.95

$       0.90

$       2.80

$       2.69

Add:

Amortization of intangible assets per share associated with acquisitions for the dialysis and ancillary operations, net of tax..................................

0.02

0.02

0.02

0.06

0.06

Amortization of intangible assets per share associated with acquisitions for the HCP operations, net of tax....................................................................

0.10

0.10

0.09

0.30

0.29

$         1.12

$        1.07

$       1.01

$       3.16

$       3.04

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands)

2.   Adjusted operating income excluding a loss contingency accrual and a settlement charge

We believe that adjusted operating income excluding a loss contingency accrual and a settlement charge enhances a user's understanding of our normal operating income for these periods by providing a measure that is meaningful because it excludes an unusual amount that was accrued as part of a settlement related to the 2010 and 2011 U.S. Attorney physician relationship investigations, as well as a settlement charge and accordingly, are comparable to prior periods and indicative of consistent operating income. These measures are not measures of financial performance under GAAP and should not be considered as an alternative to operating income.

Adjusted operating income excluding a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations, and a settlement charge related to the Vainer suit:

Three months ended

Nine months ended

September 30,

2015

June 30,

2015

September 30,

2014

September 30,

2015

September 30,

2014

Operating income..........................................................

$   509,368

$  480,548

$    437,536

$    925,760

$  1,363,056

Add:

Loss contingency accrual......................................

17,000

17,000

Settlement charge...................................................

495,000

Adjusted operating income............................................

$    509,368

$  480,548

$    454,536

$  1,420,760

$  1,380,056

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands)

3.   Effective income tax rates and adjusted effective income tax rates

We believe that reporting the effective income tax rate attributable to DaVita HealthCare Partners Inc. as well as the adjusted effective income tax rate attributable to DaVita HealthCare Partners Inc., excluding a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations, as well as a settlement charge and tax adjustment related to the settlement of the Vainer suit, enhances an investor's understanding of DaVita HealthCare Partners Inc.'s effective income tax rate and DaVita HealthCare Partners Inc.'s adjusted effective income tax rate for the periods presented because it excludes noncontrolling owners' income that primarily relates to non-tax paying entities and unusual amounts that include a loss contingency accrual and a settlement charge and tax adjustment related to the settlement of the Vainer suit, and, therefore, are meaningful to an investor to fully understand the related income tax effects on DaVita HealthCare Partners Inc.'s operating results. These are not measures under GAAP and should not be considered as an alternative to the effective income tax rate calculated in accordance with GAAP.

Effective income tax rate as compared to the effective income tax rate attributable to DaVita HealthCare Partners Inc. is as follows:

Three months ended

Nine months ended

September 30, 2015

September 30,

2015

June 30,

2015

September 30,

2014

Income from continuing operations before income taxes.....

$    408,371

$  330,539

$  336,412

$  576,829

Income tax expense.............................................................

$    147,064

$  122,762

$  116,628

$  183,893

Effective income tax rate.....................................................

36.0%

37.1%

34.7%

31.9%

Three months ended

Nine months ended

September 30, 2015

September 30,

2015

June 30,

2015

September 30,

2014

Income from continuing operations before income taxes.......................

$ 408,371

$330,539

$  336,412

$  576,829

Less:   Noncontrolling owners' income primarily attributable to non-tax paying entities.........................................................................................

(45,559)

(37,622)

(35,810)

(117,717)

Income before income taxes attributable to DaVita HealthCare Partners Inc............................................................................................

$  362,812

$292,917

$  300,602

$  459,112

Income tax expense...............................................................................

$147,064

$122,762

$  116,628

$  183,893

Less: Income tax attributable to noncontrolling interests.......................

(124)

(322)

(148)

(513)

Income tax expense attributable to DaVita HealthCare Partners Inc. .........................................................................................................

$   146,940

$  122,440

$  116,480

$ 183,380

Effective income tax rate attributable to DaVita HealthCare Partners Inc. ...........................................................................................

40.5%

41.8%

38.7%

39.9%

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands)

Three months ended

Nine months ended

September 30, 2015

Adjusted effective income tax rates attributable to DaVita HealthCare Partners Inc. excluding a loss contingency accrual related to the 2010 and 2011 U.S. Attorney physician relationship investigations, and a settlement charge and tax adjustment related to the settlement of the Vainer suit:

September 30,

2015

June 30,

2015

September 30,

2014

Income from continuing operations before income taxes..........................

$  408,371

$  330,539

$  336,412

$  576,829

Add:  

Loss contingency accrual..................................................................

17,000

Settlement charge................................................................................

495,000

408,371

330,539

353,412

1,071,829

Less:   Noncontrolling owners' income primarily attributable to non-tax paying entities...................................................................................

(45,559)

(37,622)

(35,810)

(117,717)

Adjusted income before income taxes attributable to DaVita HealthCare Partners Inc.............................................................................

$  362,812

$  292,917

$  317,602

$  954,112

Income tax expense..........................................................................................

$  147,064

$  122,762

$  116,628

$  183,893

Add:  

Income taxes attributable to the loss contingency accrual..........

6,588

Income taxes attributable to the settlement charge.......................

197,747

Tax adjustment related to the settlement of the Vainer suit......................

(7,501)

(7,501)

Less: Income tax attributable to noncontrolling interests.........................

(124)

(322)

(148)

(513)

Adjusted income tax attributable to DaVita HealthCare Partners Inc......

$  146,940

$  114,939

$  123,068

$  373,626

Adjusted effective income tax rate attributable to DaVita HealthCare Partners Inc.................................................................................................

40.5%

39.2%

38.7%

39.2%

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands)

4.  Free cash flow and adjusted operating cash flow

Free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests and capital expenditures for routine maintenance and information technology. We believe free cash flow is a useful adjunct to cash flow from operating activities and other measurements under GAAP, since free cash flow is a meaningful measure of our ability to fund acquisitions and development activities and meet our debt service requirements. In addition, free cash flow excluding distributions to noncontrolling interests provides an investor with an understanding of free cash flows that are attributable to DaVita HealthCare Partners Inc. We have also presented adjusted operating cash flow excluding the payments made in the second quarter of 2015 related to the settlement of the Vainer suit and in the fourth quarter of 2014 related to the settlement of the 2010 and 2011 U.S. Attorney physician relationship investigations, net of tax, in each case. We believe this measure is meaningful to investors to understand our operating cash flows that were generated excluding these unusual payments that were part of the settlements. Free cash flow and adjusted operating cash flow are not measures of financial performance under GAAP and should not be considered as an alternative to cash flows from operating, investing or financing activities, as an indicator of cash flows or as a measure of liquidity.

Three months ended

Nine months ended

September 30, 2015

September 30,

2015

June 30,

2015

September 30,

2014

Cash provided by operating activities........................................................

$   678,996

$    31,442

$  847,900

$  1,120,527

Less:  Distributions to noncontrolling interests..........................................

(46,898)

(37,541)

(39,325)

(125,938)

Cash provided by (used in) operating activities attributable to DaVita HealthCare Partners Inc. ......................................................

632,098

(6,099)

808,575

994,589

Less: Expenditures for routine maintenance and information technology..................................................................................................

(75,543)

(70,757)

(68,263)

(195,310)

Free cash flow...........................................................................................

$   556,555

$  (76,856)

$  740,312

$  799,279

Rolling 12-Month Period

September 30,

2015

June 30,

2015

September 30,

2014

Cash provided by operating activities..................................................................

$ 1,050,536

$1,219,440

$  1,883,585

Less:  Distributions to noncontrolling interests.................................................

(170,134)

(162,561)

(144,733)

Cash provided by operating activities attributable to DaVita HealthCare Partners Inc..........................................................................................................

880,402

1,056,879

1,738,852

Less: Expenditures for routine maintenance and information technology......

(278,121)

(270,841)

(291,563)

Free cash flow...........................................................................................................

$    602,281

$   786,038

$  1,447,289

September 30, 2015

Three months ended

Nine months ended

Rolling twelve months ended

Cash provided by operating activities.................................................................

$678,996

$1,120,527

$1,050,536

Payment in connection with the settlement of the Vainer suit.........................

493,775

493,775

Payment in connection with the settlement of the 2010 and 2011 U.S. Attorney physician relationship investigations............................................

410,356

Related tax benefit...................................................................................................

(190,246)

(331,733)

Adjusted operating cash flow...............................................................................

$678,996

$1,424,056

$1,622,934

DAVITA HEALTHCARE PARTNERS INC. RECONCILIATIONS FOR NON-GAAP MEASURES (unaudited) (dollars in thousands)

5.  Total care dollars under management

In California, as a result of our managed care administrative services agreements with hospitals and health plans, HCP does not assume the direct financial risk for institutional (hospital) services in most cases, but is responsible for managing the care dollars associated with both the professional (physician) and institutional services being provided for the Per Member Per Month (PMPM) fee attributable to both professional and institutional services. In cases where HCP does not assume the direct financial risk, HCP recognizes the surplus of institutional revenue less institutional expense as HCP net revenue. In addition to revenues recognized for financial reporting purposes, HCP measures its total care dollars under management, which includes the PMPM fee payable to third parties for institutional services where HCP manages the care provided to its members by the hospitals and other institutions, which are not included in GAAP revenues. HCP uses total care dollars under management as a supplement to GAAP revenues as it allows HCP to measure profit margins on a comparable basis across both the global capitation model (where HCP assumes the full financial risk for all services, including institutional services) and the risk sharing models (where HCP operates under managed care administrative services agreements where HCP does not assume the full risk). HCP believes that presenting amounts in this manner is useful because it presents its operations on a unified basis without the complication caused by models that HCP has adopted in its California market as a result of various regulations related to the assumption of institutional risk. Total care dollars under management is not a measure of financial performance computed in accordance with GAAP and should not be considered in isolation or as a substitute for revenues calculated in accordance with GAAP. Total care dollars under management includes PMPM payments received from third parties that are recorded net of expenses in our accounting records. The following table reconciles total care dollars under management to medical revenues for the periods indicated.

Three months ended

Nine months ended

September 30, 2015

September 30,

2015

June 30,

2015

September 30,

2014

Medical revenues.......................................................................

$    985,483

$  930,878

$    879,130

$   2,828,949

Less: Risk share revenue, net...................................................

(70,752)

(18,127)

(32,568)

(101,836)

Add: Institutional capitation amounts....................................

345,550

332,456

301,079

1,011,114

Total care dollars under management......................................

$ 1,260,281

$1,245,207

$ 1,147,641

$ 3,738,227

Contact: Jim Gustafson Investor Relations                                                                               DaVita HealthCare Partners Inc. (310) 536-2585

Logo - http://photos.prnewswire.com/prnh/20140318/DC85712LOGO

SOURCE DaVita HealthCare Partners Inc.